Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
| Autor: | Vanshika Singh, Sweety Samal, Ritika Khatri, Kalpana Luthra, Tripti Shrivastava, Chandresh Sharma, Rajesh Kumar, Shubbir Ahmed, Praveenkumar Murugavelu, Reshma Perween, Subrata Sinha, Hilal Ahmad Parray, Shivangi Shukla |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Respiratory viral infections
medicine.medical_specialty Inhaled delivery medicine.drug_class medicine.medical_treatment Monoclonal antibody Applied Microbiology and Biotechnology Prophylactic Subcutaneous injection Route of administration medicine Humans Respiratory system Intensive care medicine Monoclonal antibody therapy Therapeutic antibodies SARS-CoV-2 business.industry Immunization Passive Antibodies Monoclonal COVID-19 General Medicine Mini-Review Intranasal Nasal spray Drug delivery Nasal administration Immunotherapy business Biotechnology |
| Zdroj: | Applied Microbiology and Biotechnology |
| ISSN: | 1432-0614 0175-7598 |
| Popis: | The route of administration of a therapeutic agent has a substantial impact on its success. Therapeutic antibodies are usually administered systemically, either directly by intravenous route, or indirectly by intramuscular or subcutaneous injection. However, treatment of diseases contained within a specific tissue necessitates a better alternate route of administration for targeting localised infections. Inhalation is a promising non-invasive strategy for antibody delivery to treat respiratory maladies because it provides higher concentrations of antibody in the respiratory airways overcoming the constraints of entry through systemic circulation and uncertainity in the amount reaching the target tissue. The nasal drug delivery route is one of the extensively researched modes of administration, and nasal sprays for molecular drugs are deemed successful and are presently commercially marketed. This review highlights the current state and future prospects of inhaled therapies, with an emphasis on the use of monoclonal antibodies for the treatment of respiratory infections, as well as an overview of their importance, practical challenges, and clinical trial outcomes. Key points • Immunologic strategies for preventing mucosal transmission of respiratory pathogens. • Mucosal-mediated immunoprophylaxis could play a major role in COVID-19 prevention. • Applications of monoclonal antibodies in passive immunisation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|